Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Andrew Mould

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Contemporary Clinical Trials|May 5, 2026
Conducting multicenter trials through the trial innovation network comprehensive consultationDaniel F Hanley, Karen Lane, Nichol McBee, et al.
Journal of Clinical and Translational Science|July 30, 2025
Insights from the trial innovation network's initial consultation processPaul A Harris, Nan Kennedy, Consuelo H Wilkins, et al.
Lancet (London, England)|February 12, 2019
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trialDaniel F Hanley, Richard E Thompson, Michael Rosenblum, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Contemporary Clinical Trials|May 5, 2026
Conducting multicenter trials through the trial innovation network comprehensive consultationDaniel F Hanley, Karen Lane, Nichol McBee, et al.
Journal of Clinical and Translational Science|July 30, 2025
Insights from the trial innovation network's initial consultation processPaul A Harris, Nan Kennedy, Consuelo H Wilkins, et al.
Lancet (London, England)|February 12, 2019
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trialDaniel F Hanley, Richard E Thompson, Michael Rosenblum, et al.
Pageof 3